

Celine Bourgier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/323379/publications.pdf>

Version: 2024-02-01

38
papers

1,181
citations

394421

19
h-index

395702

33
g-index

58
all docs

58
docs citations

58
times ranked

1715
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results. <i>Quality of Life Research</i> , 2021, 30, 91-103.	3.1	7
2	Radio-induced cardiotoxicity: From physiopathology and risk factors to adaptation of radiotherapy treatment planning and recommended cardiac follow-up. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020, 24, 576-585.	1.4	12
3	Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. <i>Clinical Chemistry</i> , 2020, 66, 1093-1101.	3.2	33
4	Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 1039-1051.	0.8	10
5	The 2018 assisi think tank meeting on breast cancer: International expert panel white paper. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102967.	4.4	10
6	Quantitative proteomic analysis reveals AK2 as potential biomarker for late normal tissue radiotoxicity. <i>Radiation Oncology</i> , 2019, 14, 142.	2.7	8
7	REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 138, 59-67.	0.6	53
8	Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients With Head and Neck Cancer: Results of the Biology-Driven Phase 2 Clinical Trial Pravacur. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 365-373.	0.8	26
9	ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. <i>Radiotherapy and Oncology</i> , 2019, 137, 159-166.	0.6	80
10	The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 207-213.	4.4	7
11	External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience. <i>Breast</i> , 2018, 37, 36-41.	2.2	31
12	Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial. <i>Oncotarget</i> , 2018, 9, 15757-15765.	1.8	11
13	Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology. <i>Oncologist</i> , 2018, 23, 1289-1299.	3.7	31
14	In Regard to Pereira etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 490-491.	0.8	1
15	Personalizing Breast Cancer Irradiation Using Biology: From Bench to the Accelerator. <i>Frontiers in Oncology</i> , 2018, 8, 83.	2.8	5
16	Management of the Axilla in the Era of Breast Cancer Heterogeneity. <i>Frontiers in Oncology</i> , 2018, 8, 84.	2.8	6
17	Preoperative radiotherapy in breast cancer patients: 32Âyears of follow-up. <i>European Journal of Cancer</i> , 2017, 76, 45-51.	2.8	40
18	T lymphocytes to predict radiation-induced late effects in normal tissues. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 119-127.	3.1	19

#	ARTICLE	IF	CITATIONS
19	One Size Fits All: Does the Dogma Stand in Radiation Oncology?. EBioMedicine, 2016, 10, 19-20.	6.1	2
20	Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial. Annals of Oncology, 2016, 27, 474-480.	1.2	28
21	Feasibility of accelerated partial breast irradiation with volumetric-modulated arc therapy in elderly and frail patients. Radiation Oncology, 2015, 10, 209.	2.7	8
22	Late side-effects after curative intent radiotherapy: Identification of hypersensitive patients for personalized strategy. Critical Reviews in Oncology/Hematology, 2015, 93, 312-319.	4.4	20
23	Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer. Annals of Oncology, 2015, 26, 89-94.	1.2	47
24	Epac contributes to cardiac hypertrophy and amyloidosis induced by radiotherapy but not fibrosis. Radiotherapy and Oncology, 2014, 111, 63-71.	0.6	26
25	Adjuvant radiotherapy in the management of axillary node negative invasive breast cancer: A qualitative systematic review. Critical Reviews in Oncology/Hematology, 2013, 86, 33-41.	4.4	10
26	Exclusive Alternating Chemotherapy and Radiotherapy in Nonmetastatic Inflammatory Breast Cancer: 20 Years of Follow-Up. International Journal of Radiation Oncology Biology Physics, 2012, 82, 690-695.	0.8	19
27	Effect of preoperative rescue concomitant FUN/XUN-based chemo-radiotherapy for neoadjuvant chemotherapy-refractory breast cancer. Radiotherapy and Oncology, 2012, 103, 151-154.	0.6	15
28	Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics?. Cancer and Metastasis Reviews, 2012, 31, 699-712.	5.9	41
29	Identifying patients at risk for late radiation-induced toxicity. Critical Reviews in Oncology/Hematology, 2012, 84, e35-e41.	4.4	40
30	Higher toxicity with 42 Gy in 10 fractions as a total dose for 3D-conformal accelerated partial breast irradiation: results from a dose escalation phase II trial. Radiation Oncology, 2012, 7, 141.	2.7	17
31	Early Side Effects of Three-Dimensional Conformal External Beam Accelerated Partial Breast Irradiation to a Total Dose of 40 Gy in One Week (A Phase II Trial). International Journal of Radiation Oncology Biology Physics, 2011, 81, 1228-1235.	0.8	20
32	Radiotherapy for invasive breast cancer: Guidelines for clinical practice from the French expert review board of Nice/Saint-Paul de Vence. Critical Reviews in Oncology/Hematology, 2011, 79, 91-102.	4.4	53
33	Breast radiotherapy as part of loco-regional treatments in stage IV breast cancer patients with oligometastatic disease. Radiotherapy and Oncology, 2010, 96, 199-203.	0.6	59
34	Partial breast irradiation: new standard for selected patients. Lancet, The, 2010, 376, 71-72.	13.7	24
35	Counterpoint: Conformal external beam for accelerated partial breast irradiation. Brachytherapy, 2009, 8, 184-188.	0.5	9
36	Pravastatin Inhibits the Rho/CCN2/Extracellular Matrix Cascade in Human Fibrosis Explants and Improves Radiation-Induced Intestinal Fibrosis in Rats. Clinical Cancer Research, 2007, 13, 5331-5340.	7.0	126

#	ARTICLE	IF	CITATIONS
37	Successful Mitigation of Delayed Intestinal Radiation Injury Using Pravastatin is not Associated with Acute Injury Improvement or Tumor Protection. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1471-1482.	0.8	67
38	Inhibition of Rho kinase modulates radiation induced fibrogenic phenotype in intestinal smooth muscle cells through alteration of the cytoskeleton and connective tissue growth factor expression. <i>Gut</i> , 2005, 54, 336-343.	12.1	98